Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory
pathways of the immune system to fight cancer cells. Their use is often limited by the …

Immune-mediated necrotising myopathy (IMNM) is a relatively recently described form of
idiopathic inflammatory myopathy (IIM) that is characterised by progressive proximal …

Introduction An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs)
may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) …

Immune checkpoint inhibitors have advanced the treatment paradigm of various cancers,
achieving remarkable survival benefits. However, a myriad of immune-related adverse …

The correlation between clinical outcomes and treatment-related adverse events (AEs) has
always been a debated topic in clinical oncology. Despite toxicities pharmacodynamics …

Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse
events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies …